Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 2/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657016 | 0.87 | HDAC1 (0.49) | CDK4CCNE1CDK2HDAC1HDAC6 | |
| SCHEMBL655677 | 0.87 | CCNE1 (0.33) | CDK4CCNE1CDK2HDAC1HDAC6 | |
| SCHEMBL3357617 | 0.87 | CCNE1 (0.40) | CDK4CCNE1CDK2HDAC1HDAC6 | |
| SCHEMBL659399 | 0.85 | CCNE1 (0.33) | CDK4CCNE1CDK2HDAC1HDAC6 | |
| SCHEMBL658247 | 0.85 | HDAC1 (0.39) | CDK4CCNE1CDK2HDAC1HDAC6 | |
| SCHEMBL657216 | 0.84 | CDK2 (0.37) | CDK4CCNE1CDK2HDAC1HDAC6 | |
| SCHEMBL658594 | 0.84 | HDAC6 (0.34) | HDAC1HDAC6HDAC8HDAC3HDAC2 | |
| SCHEMBL657967 | 0.82 | AKT1 (0.42) | CDK4CCNE1CDK2HDAC1HDAC6 | |
| SCHEMBL700690 | 0.81 | CAMK2D (0.47) | CDK4CCNE1CDK2HDAC1HDAC6 | |
| SCHEMBL3348358 | 0.81 | CDK2 (0.52) | CDK4CCNE1CDK2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-02-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | CDK4 276/4885CCNE1 1992/4885CDK2 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.